Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by priceless2on Jan 24, 2015 3:47pm

232 Views

Post# 23359659

RE:RE:RE:RE:RE:RE:RE:RE:PIII trial design questions...is there a biostatitician here

Rvx street,

I agree 100% that if this phase 3 trial succeeds rvx 208 will be a blockbuster drug. What would be a fair market value at that point. .? I suspect tha Don and company including ngn and Ken Dart feel that rvx 208 alone is worth a lot, which may be the reason BP is waiting for some data from the phase 3 trial before making a huge jump.

Bullboard Posts

How a junior advances one of the largest undeveloped diamond projects